Skip to main content

Table 1 Hepatotoxicity related to erlotinib administration

From: Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study

Characteristics All patients Lung cancer Pancreatic cancer
Hepatotoxicity No (%) Hepatotoxicity No (%) Hepatotoxicity No (%)
Presence (n = 62) Absence (n = 298) Presence (n = 16) Absence (n = 139) Presence (n = 46) Absence (n = 159)
Age (years)
  < 65 28 (45.2) 155 (52.0) 6 (37.5) 85 (61.2) 22 (47.8) 70 (44.0)
  ≥ 65 34 (54.8) 143 (48.0) 10 (62.5) 54 (38.8) 24 (52.2) 89 (56.0)
Sex
 Male 35 (56.5) 182 (61.1) 8 (50.0) 87 (62.6) 27 (58.7) 95 (59.7)
 Female 27 (43.5) 116 (38.9) 8 (50.0) 52 (37.4) 19 (41.3) 64 (40.3)
BW (kg)
  < 60 38 (61.3) 162 (54.4) 6 (37.5) 70 (50.4) 32 (69.6) 92 (57.9)
  ≥ 60 24 (38.7) 136 (45.6) 10 (62.5) 69 (49.6) 14 (30.4) 67 (42.1)
Height (cm)a
  < 160 27 (43.5) 115 (38.7) 8 (50.0) 45 (32.4) 19 (41.3) 70 (44.3)
  ≥ 160 35 (56.5) 182 (61.3) 8 (50.0) 94 (67.6) 27 (58.7) 88 (55.7)
BSAb
  < 1.6 32 (51.6) 130 (43.8) 5 (31.3) 54 (38.8) 27 (58.7) 76 (48.1)
  ≥ 1.6 30 (48.4) 167 (56.2) 11 (68.6) 85 (61.2) 19 (41.3) 82 (51.9)
Stagec
 1–3 6 (14.3) 27 (14.4) 0 (0.0) 5 (5.0) 6 (20.7) 22 (25.0)
 4 36 (85.7) 161 (85.6) 13 (100.0) 95 (95.0) 23 (79.3) 66 (75.0)
CV
 Yes 15 (24.2) 83 (27.9) 1 (6.3) 25 (18.0) 14 (30.4) 58 (36.5)
 No 47 (75.8) 215 (72.1) 15 (93.8) 114 (82.0) 32 (69.6) 101 (63.5)
DM
 Yes 18 (29.0) 66 (22.1) 1 (6.3) 17 (12.2) 17 (37.0) 49 (30.8)
 No 44 (71.0) 232 (77.9) 15 (93.8) 122 (87.8) 29 (63.0) 110 (69.2)
EGFR mutationsd
 Yes 9 (81.8) 76 (69.1) 9 (81.8) 76 (69.1) NA NA
 No 2 (18.2) 34 (30.9) 2 (18.2) 34 (30.9) NA NA
Liver metastasis
 Yes 19 (30.6) 61 (20.5) 2 (12.5) 11 (7.9) 17 (37.0) 50 (31.4)
 No 43 (69.4) 237 (79.5) 14 (87.5) 128 (92.1) 29 (63.0) 109 (68.6)
CYP3A4 Inhibitor
 Yes 3 (4.8) 15 (5.0) 2 (12.5) 10 (7.2) 1 (2.2) 5 (3.1)
 No 59 (95.2) 283 (95.0) 14 (87.5) 129 (92.8) 45 (97.8) 154 (96.9)
CYP3A4 Inducer
 Yes 7 (11.3) 15 (5.0) 3 (18.8) 11 (7.9) 4 (8.7) 4 (2.5)
 No 55 (88.7) 283 (95.0) 13 (81.3) 128 (92.1) 42 (91.3) 155 (97.5)
H2 blocker or PPI
 Yes 16 (25.8) 56 (18.8) 7 (43.8) 28 (20.1) 9 (19.6) 28 (17.6)
 No 46 (74.2) 242 (81.2) 9 (56.3) 111 (79.9) 37 (80.4) 131 (82.4)
PPI
 Yes 7 (11.3) 23 (7.7) 4 (25.0) 12 (8.6) 3 (6.5) 11 (6.9)
 No 55 (88.7) 275 (92.3) 12 (75.0) 127 (91.4) 43 (93.5) 148 (93.1)
H2 blocker
 Yes 9 (14.5) 41 (13.8) 3 (18.8) 22 (15.8) 6 (13.0) 19 (11.9)
 No 53 (85.5) 257 (86.2) 13 (81.3) 117 (84.2) 40 (87.0) 140 (88.1)
  1. BW body weight, BSA body surface area, ECOG PS Eastern Cooperative Oncology Group performance scale, CV Cardiovascular diseases, DM Diabetes Mellitus, EGFR epidermal growth factor receptor, PPI proton pump inhibitor, NA not available
  2. aThere was 1 missing data for height
  3. bThere was 1 missing data for BSA
  4. cThere were 130 missing data for stage
  5. dThere were 34 missing data for EGFR mutation in lung cancer patients